Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial

Jeremy Cottrell, Kerstin Koenig, Roland Perfekt, Robert Hofmann, Loperamide–Simethicone Acute Diarrhoea Study Team, J E R Orozco, H O E Picazo, R Maxwell, E M Espino, D Naik, V Naik, Jeremy Cottrell, Kerstin Koenig, Roland Perfekt, Robert Hofmann, Loperamide–Simethicone Acute Diarrhoea Study Team, J E R Orozco, H O E Picazo, R Maxwell, E M Espino, D Naik, V Naik

Abstract

Background: Acute diarrhoea is a frequent health problem in both travellers and residents that has a social and economic impact. This study compared the efficacy and tolerability of two loperamide-simeticone formulations and a Saccharomyces boulardii capsule as symptomatic treatment.

Methods: This was a prospective, randomised, single (investigator)-blind, three-arm, parallel group, non-inferiority clinical trial in adult subjects with acute diarrhoea at clinics in Mexico and India, with allocation to a loperamide-simeticone 2/125 mg caplet or chewable tablet (maximum eight in 48 h) or S. boulardii (250 mg twice daily for 5 days).

Outcome measures: The primary outcome measure was the number of unformed stools between 0 and 24 h following the initial dose of study medication (NUS 0-24). The secondary outcome measures were time to last unformed stool (TLUS), time to complete relief of diarrhoea (TCRD), time to complete relief of abdominal discomfort (TCRAD) and the subject's evaluation of treatment effectiveness. Follow-up endpoints at 7 days were feeling of complete wellness; stool passed since final study visit; and continued or recurrent diarrhoea.

Subjects: In this study, 415 subjects were randomised to either a loperamide-simeticone caplet (n = 139), loperamide-simeticone chewable tablet (n = 139) or S. boulardii capsule (n = 137) and were included in the intention-to-treat analysis.

Results: With regards to mean NUS 0-24, the loperamide-simeticone caplet was non-inferior to loperamide-simeticone tablets (3.4 vs. 3.3; one-sided 97.5 % confidence interval ≤0.5), with both significantly lower than S. boulardii (4.3; p < 0.001). The loperamide-simeticone groups had a shorter median TLUS [14.9 and 14.0 vs. 28.5 h (loperamide-simeticone caplet and chewable tablet groups, respectively, vs. S. boulardii); p < 0.001], TCRD (26.0 and 26.0 vs. 45.8 h; p < 0.001) and TCRAD (12.2 and 12.0 vs. 23.9 h; p < 0.005) than S. boulardii. Treatment effectiveness for overall illness, diarrhoea and abdominal discomfort relief was greater (p < 0.001) in the loperamide-simeticone groups than with S. boulardii. At 7-day follow-up most subjects reported passing stool at least once since the final study visit (loperamide-simeticone caplet 94.1 %, loperamide-simeticone chewable tablet 94.8 %, S. boulardii 97.0 %), did not experience continued or recurrent diarrhoea [loperamide-simeticone caplet 3.7 % (p < 0.03 vs. S. boulardii), loperamide-simeticone chewable tablet 3.7 %, S. boulardii 5.7 %] and felt completely well [loperamide-simeticone caplet 96.3 % (p < 0.02 vs. S. boulardii), loperamide-simeticone chewable tablet 96.3 % (p < 0.02 vs. S. boulardii), S. boulardii 88.6 %]. All treatments were well-tolerated with few adverse events.

Conclusions: The loperamide-simeticone caplet was non-inferior to the original loperamide-simeticone chewable tablet formulation; both formulations can be expected to demonstrate similar clinical efficacy in the relief of symptoms of acute diarrhoea. Both loperamide-simeticone formulations were superior to the S. boulardii capsule in the primary and secondary endpoints.

Clinical trial registration: ClinicalTrials.gov identifier NCT00807326.

Figures

Fig. 1
Fig. 1
Study flow diagram. ITT intention-to-treat
Fig. 2
Fig. 2
Time to last unformed stool (Kaplan–Meier curve)
Fig. 3
Fig. 3
Time to complete relief of diarrhoea (Kaplan–Meier curve)

References

    1. Manatsathit S, DuPont HL, Farthing M, et al. Working Party of the Program Committee of the Bangkok World Congress of Gastroenterology 2002. Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol. 2002;17(Suppl):S54–S71. doi: 10.1046/j.1440-1746.17.s1.11.x.
    1. von Sonnenburg F, Tomieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet. 2000;356:133–134. doi: 10.1016/S0140-6736(00)02451-X.
    1. Steffen R. Epidemiology of traveler’s diarrhea. Clin Infect Dis. 2005;41(suppl 8):S536–S540. doi: 10.1086/432948.
    1. Wingate D, Phillips SF, Lewis SJ, et al. Guidelines for adults on self-medication for the treatment of acute diarrhoea. Aliment Pharmacol Ther. 2001;15:773–782. doi: 10.1046/j.1365-2036.2001.00993.x.
    1. DuPont HL, Ericsson CD, Farthing MJG, et al. Expert review of the evidence base for self-therapy of travelers’ diarrhea. J Travel Med. 2009;16:161–171. doi: 10.1111/j.1708-8305.2009.00300.x.
    1. Kennedy J. Self care of acute diarrhoea in non-travelling adults. SelfCare. 2010;1:50–53.
    1. Farthing M, Salam M, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47:12–20. doi: 10.1097/MCG.0b013e31826df662.
    1. Kaplan MA, Prior MJ, Ash RR, et al. Loperamide–simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort. Arch Fam Med. 1999;8:243–248. doi: 10.1001/archfami.8.3.243.
    1. Hanauer SB, DuPont HL, Cooper KM, et al. Randomized, double-blind, placebo controlled clinical trial of loperamide plus simethicone vs. loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007;23:1033–1043. doi: 10.1185/030079907X182176.
    1. Connor AL, Wray H, Cottrell J, et al. A scintigraphic study to investigate the potential for altered gut distribution of loperamide from a loperamide–simethicone formulation in man. Eur J Pharm Sci. 2001;13:369–374. doi: 10.1016/S0928-0987(01)00132-4.
    1. Placidi E, Marciani L, Hoad CL, et al. The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea. Aliment Pharmacol Ther. 2012;36:64–73. doi: 10.1111/j.1365-2036.2012.05127.x.
    1. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics—Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26:767–778. doi: 10.1111/j.1365-2036.2007.03442.x.
    1. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:257–264. doi: 10.1111/j.1365-2036.2006.03202.x.
    1. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010;10:CD003048.
    1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202–2222. doi: 10.3748/wjg.v16.i18.2202.
    1. Keseledis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012;5(2):111–125. doi: 10.1177/1756283X11428502.
    1. Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Exp Opin Pharmacother. 2012;13(1):17–26. doi: 10.1517/14656566.2011.634800.
    1. Dinleyici EC, Eren M, Ozen M, et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Exp Opin Biol Ther. 2012;13(1):17–26.
    1. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938. doi: 10.1371/journal.pone.0034938.
    1. Feizizadeh S, Amin Salehi-Abargouei A, Vajihe Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134:e176–e191. doi: 10.1542/peds.2013-3950.
    1. Passariello A, Agricole P, Malfertheiner P. A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin. 2014;30(6):1055–1064. doi: 10.1185/03007995.2014.898138.
    1. Peltola H, Gorbach SL. Travelers’ diarrhea. In: DuPont HL, Steffen R, editors. Textbook of travel medicine and health. Hamilton: B C Decker Inc.; 2001.
    1. Bouckenooghe AR, Jiang ZD, de la Cabada FJ, et al. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med. 2002;9:137–140. doi: 10.2310/7060.2002.23206.
    1. Spina A, Kerr KG, Cormican M, et al. Spectrum of enteropathogens detected by the FilmArray GI Panel in a multicentre study of community-acquired gastroenteritis. Clin Microbiol Infect. 2015;21:719–728. doi: 10.1016/j.cmi.2015.04.007.
    1. European Medicines Agency. ICH Topic E 10: choice of control group in clinical trials. Note for guidance on choice of control group in clinical trials (CPMP/ICH/364/96) January 2001. . Accessed 5 Oct 2015.
    1. Bruns R, Raedsch R. Therapy of traveller’s diarrhea [in German] Med Welt. 1995;46:591–596.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa